Clinical trial to evaluate efficacy of Isolagen Therapy for treating acne scars

December 4, 2007

Exton, Pa. - Biotech company Isolagen, based here, has announced the initiation of a phase 3 clinical study to test Isolagen Therapy for the treatment of moderate to severe acne scars, PRNewswire reports.

Exton, Pa. - Biotech company Isolagen, based here, has announced the initiation of a phase 3 clinical study to test Isolagen Therapy for the treatment of moderate to severe acne scars, PRNewswire reports.

The clinical testing consists of two randomized, double-blind, placebo-controlled trials. All patients will receive active treatment on one side of the face and placebo on the other.

Patients will receive three injections of Isolagen Therapy, two weeks apart, and be followed for four months after the final treatment.

The company also has a phase 3 clinical program under way to evaluate Isolagen Therapy in treating nasolabial folds.